title: [Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
abstract: After the ROCKET AF study main paper several subgroups analysis were recently published. These studies are useful to better evaluate the rivaroxaban efficacy and safety in different clinical conditions. Here the subgroup analysis of patients with moderate renal failure, heart failure and diabetes are presented. Post hoc data on patients who underwent an electrical or pharmacological cardioversion during ROKET AF follow up were available and here we analyze also the results of the first randomized study on electrical cardioversion in patients treated with new oral anticolagulants: the X-VeRT trial. A metanalysis of all the studies with rivaroxaban (one on stroke prevention in atrial fibrillation, two on acute coronary syndromes, four on deep venous thrombosis prophylaxis and two on pulmonary embolism treatment) with respect to the risk of myocardial infarction is examined.
authors.forename: Cesare
authors.initials: C
authors.lastname: Greco
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000628:therapy; D004554:Electric Countershock; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban